GRCL Gracell Biotechnologies ADS (N Shares)

Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium

Gracell Biotechnologies to Participate in Truist Securities Cell Therapy Symposium

SAN DIEGO and SUZHOU and SHANGHAI, China, June 20, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that the management team will participate and host investor meetings in the Truist Securities Cell Therapy Symposium: Symposia-cel on June 27, 2023, in New York, NY.

For more information, please visit .

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune disease. For more information on Gracell, please visit . Follow @GracellBio on .



Media contacts
Marvin Tang
 
Jessica Laub
 

Investor contacts
Gracie Tong
 
Stephanie Carrington
EN
20/06/2023

Underlying

GRCLGracell Biotechnologies ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gracell Biotechnologies ADS (N Shares)

 PRESS RELEASE
Free
GRCL Gracell Biotech...

Gracell Biotechnologies Acquisition Completed

Gracell Biotechnologies Acquisition Completed SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the ...

February 22, 2024 1 EN
 PRESS RELEASE
Free
GRCL Gracell Biotech...

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agr...

Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the “EGM”) held on February 19, 2024, the Company’s shareholders voted in favor of the proposal to approve and au...

February 20, 2024 1 EN
 PRESS RELEASE
Free
GRCL Gracell Biotech...

Gracell Biotechnologies Announces FDA Clearance of IND Application for...

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma SAN DIEGO and SUZHOU, China and SHANGHAI, China, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacio...

January 29, 2024 1 EN
 PRESS RELEASE
Free
GRCL Gracell Biotech...

Gracell Biotechnologies Announces China NMPA Clearance for IND Applica...

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-cells FasTCAR-T GC012F has demonstrated a favorable safety profile in clinical investigator-initiated trials in 60 ...

December 21, 2023 1 EN
 PRESS RELEASE
Free
GRCL Gracell Biotech...

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T ...

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023 Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months GC012F is a FasTCAR-enabled B-cell maturation antigen (BCMA) and CD19 dual-targeting autologous CAR-T therapy being evaluated for hematologic malignancies and autoimmune disease SAN DIEGO and SUZHOU, China and SHANGHAI, China, D...

December 12, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch